Retatrutide Prescribed Online to Pennsylvania Residents
Medical Weight Loss Treatment in Pennsylvania
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Pennsylvania
The Keystone State connects America—and OmniRx Health connects Pennsylvanians with quality care. From Philadelphia's historic streets to Pittsburgh's tech revival, the Amish country of Lancaster to the wilds of the Poconos, we serve the entire Commonwealth. Our telehealth platform is ideal for busy professionals in the cities, rural residents far from specialists, and everyone in between who values convenient, quality healthcare without the hassle of traditional appointments.
Our providers are licensed by the Pennsylvania State Board of Medicine for comprehensive telehealth services statewide.
Pennsylvania's extensive pharmacy network from Philadelphia to Pittsburgh and throughout rural areas ensures prescription access.
Pennsylvania has comprehensive telehealth laws that support virtual care while maintaining quality and safety standards.
Pennsylvania requires telehealth coverage, with commercial insurers and Medicaid providing virtual visit benefits.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Pennsylvania?
- Yes, telehealth is fully legal in Pennsylvania. The Commonwealth has comprehensive regulations supporting virtual healthcare delivery by licensed providers.
- Can rural Pennsylvania residents use telehealth?
- Telehealth is transforming rural PA healthcare. Residents in the Poconos, central Pennsylvania, and other less-served areas can access specialists without long drives.
- Does Pennsylvania insurance cover telehealth?
- Yes, Pennsylvania requires telehealth coverage for commercial insurers and Medicaid. Most plans cover virtual visits at rates comparable to in-person care.